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ABSTRACT
Objectives Post- traumatic stress disorder (PTSD) is 
commonly experienced in the aftermath of major incidents 
such as terrorism and pandemics. Well- established 
principles of response include effective and scalable 
treatment for individuals affected by PTSD. In England, 
such responses have combined proactive outreach, 
screening and evidence- based interventions (a ‘screen- 
and- treat’ approach), but little is known about its cost- 
effectiveness. The objective of this paper is to report the 
first systematic attempt to assess the cost- effectiveness of 
this approach.
Methods A decision modelling analysis was undertaken 
to estimate the costs per quality- adjusted life- year (QALY) 
gained from a screen- and- treat approach compared with 
treatment- as- usual, the latter involving identification of 
PTSD by general practitioners and referral to psychological 
therapy services. Model input variables were drawn from 
relevant empirical studies in the context of terrorism 
and the unit costs of health and social care in England. 
The model was run over a 5- year time horizon for a 
hypothetical cohort of 1000 exposed adults from the 
perspective of the National Health Service and Personal 
Social Services in England.
Results The incremental cost per QALY gained was 
£7931. This would be considered cost- effective 88% of 
the time at a willingness- to- pay threshold of £20 000 per 
QALY gained, the threshold associated with the National 
Institute for Health and Care Excellence in England. 
Sensitivity analysis confirmed this result was robust.
Conclusions A screen- and- treat approach for identifying 
and treating PTSD in adults following terrorist attacks 
appears cost- effective in England compared with 
treatment- as- usual through conventional primary care 
routes. Although this finding was in the context of 
terrorism, the implications might be translatable into other 
major incident- related scenarios including the current 
COVID- 19 pandemic.
INTRODUCTION
Post- traumatic stress disorder (PTSD), a 
severe and chronic condition associated with 
high levels of functional impairment, is the 
most common single psychiatric outcome 
of major incidents worldwide, including 
pandemics.1–4 Following exposure to a 
terrorist attack, for example, adult victims 
have a prevalence of PTSD estimated at 
30%–40%.5 Despite the existence of effective 
psychological therapies, PTSD often remains 
untreated, whether or not it occurs in the 
context of a major incident.6–8 The reasons 
for this are well understood: a combination 
of low priority at strategic planning and 
policy development level, general low levels 
of public understanding, poor recognition in 
primary care and the avoidance that is one of 
the defining symptoms.6 9 10 In recent years, 
health systems have begun to address this 
problem by instituting proactive outreach 
to affected populations, often coupled with 
screening and signposting into evidence- 
based treatments.11–14 In this paper, we report 
the first systematic attempt to assess the cost- 
effectiveness of this approach. Data are taken 
from studies of terrorist attacks affecting UK 
residents, but our conclusions provide some 
implications for other major incidents and 
can inform responses to COVID- 19 where 
PTSD is a common problem.15
It is important to highlight upfront that 
psychological reactions to trauma vary in 
severity and duration. The majority of indi-
viduals directly exposed to trauma will not 
develop PTSD, as many symptoms of distress 
will naturally decline and are unlikely to have 
long- term implications.1 5 A sizeable minority 
require mental health services and a small 
proportion need long- term intervention.
Strengths and limitations of this study
 ► Emerging economic data on screen- and- treat pro-
grammes are synthesised for the first time.
 ► The model is based on actual clinical practice and 
closely follows National Institute for Health and Care 
Excellence guidelines.
 ► Exclusion of indirect costs may have led to under-
estimation of the cost- effectiveness of the screen- 
and- treat approach.
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In England, the public health approach following 
recent major incidents has been to institute an initial 
period of ‘watchful waiting’, which for the majority will 
allow natural coping resources and social support to lead 
to spontaneous remission and mitigates the deployment 
of resources on individuals with transient conditions. 
After this initial delay, outreach and screening are offered 
to populations at high risk of developing PTSD. This is 
done using brief, validated instruments.16 A stepped 
model of care is recommended, which starts with assess-
ment and facilitates access to mental health services 
if immediate and short- term distress does not resolve. 
Trauma- focused cognitive behavioural therapy (CBT) is 
a highly effective treatment for PTSD, typically delivered 
over 8–12 sessions.17 Approaches that link evidence- based 
treatment with outreach and screening are known as 
‘screen- and- treat’ or ‘outreach- and- screen’.
There have been several bespoke screen- and- treat 
programmes implemented in England in the context 
of recent major incidents. These include the Trauma 
Response Programme following the London bombings, 
the Screen and Treat Programme following the terrorist 
attacks in Tunisia, Brussels and Paris, the Manchester 
Resilience Hub following the Manchester Arena 
bombing and the Health and Well- being Service after 
the Grenfell Tower fire in West London. Evaluations of 
those programmes have concluded that screen- and- treat 
approaches may be a clinically effective approach for 
decreasing symptoms of mental ill health and improving 
social function following major incidents.13 18–22
Economic modelling can be used to synthesise evidence 
on the effectiveness of different interventions with 
evidence on the costs and consequences of these actions. 
The approach is used as standard by the National Insti-
tute for Health and Care Excellence in England (NICE) 
when looking at the case for investing in any healthcare 
intervention. Assumptions in models can be varied to help 
provide decision makers with a range of policy- relevant 
information, including uncertainty on evidence of effect, 
as well as level of uptake and sustained use. Models can 
also be used to extrapolate longer- term impacts than 
those seen in many empirical trials.
With screen- and- treat approaches, evidence on cost- 
effectiveness as well as clinical effectiveness is vital to 
support decisions on both short- term and longer- term 
resourcing. The aim of our study is to use decision 
analytical modelling to evaluate the cost- effectiveness 
of a screen- and- treat approach for identifying and 
treating PTSD following major incidents compared with 
treatment- as- usual delivered as a result of identification 
through conventional primary care routes and subse-
quent referral to the same psychological therapy services.
METHODS
Study design and assumptions
A decision tree was constructed in Microsoft Excel 
to compare the screen- and- treat approach with 
treatment- as- usual for a hypothetical cohort of individ-
uals in England. Each pathway was assumed to consist 
of 1000 adults who were directly exposed to terrorism at 
time zero. The clinical pathway for the screen- and- treat 
intervention group was based on a simplified version of 
the mental health responses implemented following the 
London bombings in 2005 and 2017. The intervention 
pathway assumed that individuals were screened with the 
Trauma Screening Questionnaire (TSQ) at 3 months.23 
The intervention pathway compared with treatment- as- 
usual is shown in figure 1. It was not necessary to incor-
porate Markov cycles into the model as participants were 
unlikely to move any further between states after the 
initial period when treatment had been completed. Any 
spontaneous remission we also assumed would only occur 
in this period.
Participants who screened positive would have a clinical 
assessment in the form of the Structured Clinical Inter-
view for DSM- 5 (SCID- 5).24 This is a commonly employed 
measure and assumed to be 100% accurate. Individuals 
identified as ‘true positives’ would then be referred for 
CBT mainly through Improving Access to Psycholog-
ical Therapies (IAPT) services, receiving an average of 
12 individual weekly sessions over 3 months.25 Rates of 
uptake and completion of CBT were modelled separately. 
The ‘false positives’, those incorrectly identified by the 
screening tool, were screened out by the SCID- 5 as they 
did not have PTSD. Subsequently at 9 months, all partic-
ipants in the intervention pathway who had not been 
referred to treatment were screened again using the TSQ 
in an attempt to capture the ‘false negatives’ from the 
first round of screening as well as those participants that 
developed delayed- onset PTSD. The process of assess-
ment used the SCID- 5 and again referral for treatment 
with CBT was offered.
The treatment- as- usual comparator group received no 
treatment, unless the individual was detected as having 
PTSD through conventional primary care routes. Partic-
ipants in the comparator pathway with PTSD who were 
detected in primary care were also referred to IAPT 
services for treatment. At the end of the clinical pathway, 
the proportions of participants in the intervention and 
comparator groups with PTSD, partial recovery from 
PTSD, and no PTSD were calculated. Partial recovery 
from PTSD was a health state intended to reflect those 
individuals experiencing symptoms at a subclinical level.
Costs and outcomes conditional on the individual’s 
health state were simulated over a 5- year time horizon 
from a National Health Service (NHS) and Personal Social 
Services (PSS) perspective to capture the longer- term 
and wider consequences of PTSD. This is the perspective 
adopted by NICE in their appraisals. Five years is a plau-
sible time frame as we expect some persistence of effect.18 
All costs were inflated by 1.5% annually to 2018 prices 
in British Pounds (GBP) and both costs and outcomes 
were discounted over the 5- year time horizon at 3.5% per 
annum. This discount rate was chosen to reflect central 
government guidance on appraisal and evaluation.26
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It was conservatively assumed that PTSD was the only 
mental health impact, and comorbidity with other mental 
health conditions was not modelled. This simplification 
was made because, although comorbidity is high in 
psychiatric samples with PTSD and survivors of chronic 
and repeated trauma, there is no evidence this applies to 
victims of terrorist attacks who are more representative of 
the general population. In any event, PTSD represents the 
overwhelming majority of mental health need following 
terrorism and successful treatment for PTSD also leads 
to remission of comorbid conditions.5 11 27 The model was 
further simplified to ignore the risk of relapse because 
gains from CBT tend to be maintained following a single 
trauma.18 28 Furthermore, the model did not account 
for heterogeneity by demographic factors (eg, age, sex, 
ethnicity and socioeconomic status). Incremental cost 
per quality- adjusted life- year (QALY) was then calculated. 
This is the reference case measure used by NICE when 
assessing the case for investing in healthcare interventions 
and enables comparison between investment choices for 
different healthcare and public health programmes.
Model parameters
Model inputs are shown in table 1. Where possible, the 
most relevant ‘local’ parameter estimates were used. 
The prevalence of PTSD in adults was assumed to be 
31% based on the proportion of survivors that required 
treatment for PTSD following the London bombings.18 
This is consistent with an international systematic review 
finding a mean prevalence of 29.8% in adult victims of 
terrorism.29 Furthermore, it was assumed that for 85% 
of participants the onset of PTSD would be ‘immediate’ 
(occur within 3 months) and the remaining 15% would 
have a ‘delayed’ onset (at 6 months). This is consistent 
with evidence on the prevalence of delayed- onset PTSD.30
Studies analysing data from the London bombings 
were used to estimate the specificity and sensitivity of the 
TSQ at 3 months and 9 months31 and the probabilities 
of uptake of CBT, completion of CBT and recovery or 
partial recovery with CBT.18 The underlying annual risk 
of mortality in both arms of the model was assumed to 
be equivalent to the weighted average of rates for males 
and females at age 40 in England.32 We assumed a 54% 
increased risk of all- cause mortality due to PTSD, drawing 
on 9/11 World Trade Centre data for civilians only.33 
The probability of detection of PTSD in primary care was 
approximated at 5% over the time horizon of the model, 
based on studies on PTSD detection rates in conventional 
primary care settings in England,10 supported by repeated 
reports of lack of referral of survivors of terrorist attacks 
by family doctors.18 19
The probability of spontaneous remission was based 
on findings from a recent systematic review that 34.8% 
of those with PTSD following exposure to intentional 
trauma remit after 3 months.28 However, that figure was 
lowered at the discretion of the authors to 20%. This was 
for three key reasons. First, individuals who judge they are 
likely to get better on their own may not engage with the 
programme, while those who do engage may have a more 
Figure 1 Screen- and- treat clinical pathway compared with treatment- as- usual. CBT, cognitive–behavioural therapy; GPs, 
general practitioner.
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chronic course. Second, remission is based on no longer 
meeting diagnostic criteria for PTSD and in practice 
many people may have significant residual symptoms that 
could benefit from treatment. For example, they may still 
have clinical levels of depression or have a phobic condi-
tion. Third, remission in the literature has only been 
measured at one point in time and people may fluctuate 
between meeting and not meeting diagnostic criteria if 
they are followed up for longer. For example, they might 
have another onset triggered by an inquest or court case.
The costs per person for screening and assessment, 
both averaging £588, were calculated using 2015 data 
from the London bombings inflated to 2018 prices.34 
These costs included start- up and management of the 
programme, finding, screening and assessing participants 
and referral management. The cost of treatment through 
IAPT (£1710) was calculated using unit costs of health 
and social care at 2018 prices (£95) multiplied by an 
average number of 12×1.5 hours sessions.35 To be conser-
vative, we have also assumed that a minority (10%) of 
service users with more severe needs would instead make 
use of 20 hours of specialist trauma therapy delivered by 
Band 8d grade clinical psychologists with overheads at a 
cost of £3052, increasing the average cost of treatment to 
£1844.35 36
The costs of medication, healthcare, and PSS were 
approximations based on a recent expert panel review 
convened in England to review the economic evidence 
on PTSD.17 The annual costs of being in the PTSD or no 
PTSD health states were approximated by the panel as 
£1173 and £110 per person respectively at 2018 prices. 
Forecast costs included medication, inpatient hospital 
stays, outpatient visits, general practitioners and district 
nursing, outreach and home help, and psychological 
treatment. The cost of being in the partial recovery from 
PTSD health state was assumed to be mid- way between 
having PTSD and not having PTSD (£642) to capture the 
associated costs of subclinical symptoms. Our analysis is 
conservative as productivity losses arising from disrupted 
education or employment were excluded given the NHS 
and PSS perspective taken.
QALYs were used as the measurement of health gain. 
A preference- weight of ‘1’ equates to perfect health, ‘0’ 
to death, and negative values (worse than death) are 
permitted. We were unable to identify UK utility values for 
our study population, and instead the PTSD and no PTSD 
utilities, 0.610 and 0.850, respectively, were based on an 
Australian study in the context of sexual abuse.37 The 
utility value for subclinical PTSD resulting from partial 
recovery with CBT was approximated as the midpoint 
between having PTSD and not having PTSD.
We also assumed that during the initial first year of 
the model, individuals who had delayed onset PTSD and 
were only identified at the second 9- month screening 
would have the utility and costs associated with PTSD for 
6 months; and only in subsequent years, depending on 
treatment effect or spontaneous remission, would they 
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PTSD or no PTSD. This is conservative, as the delay in 
onset of PTSD will actually have meant that for some indi-
viduals their utility values will be higher (as they spent less 
time with PTSD) and their costs lower than what we now 
assume in the model.
Sensitivity analysis
One- way sensitivity analysis was conducted to test the 
robustness of the results by varying utility and proba-
bility model parameters by 10% and all costs by 20% in 
either direction (to reflect the potential for considerable 
variation).
A probabilistic sensitivity analysis with 1000 iterations 
was also conducted to vary input variables simultaneously. 
A gamma distribution was assumed for costs because the 
data are skewed and constrained between zero and posi-
tive infinity, and a beta distribution was assumed for prob-
abilities and outcomes because the data are binomial and 
constrained between zero and one. Distribution parame-
ters for utilities associated with PTSD and prevalence of 
PTSD, sensitivity and specificity of the TSQ, as well as like-
lihood of CBT completion and recovery after CBT were 
taken from previous research. For the underlying proba-
bility of mortality in the population, we assumed annual 
mortality rates might range between 3- year averages in 
England seen at age 30 and age 50. For parameters where 
distributions were not available, we had to make expert 
assumptions on plausible SEs to estimate beta and gamma 
distributions around the mean. For probabilities with 
minimal uncertainty, we assumed a SE of 0.01, with the 
exception of a large error of 0.30 reflecting uncertainty 
in uptake of intervention. In line with previous analyses, 
most costs were assumed to have an SE of 0.30, with the 
exception of therapeutic intervention costs where the SE 
was 0.05 as salary costs for psychologists delivering inter-
ventions are dependent on national pay scales.




The total costs and effects for 1000 individuals and 
the average costs and effects per person are shown 
as accrued over the 5- year time horizon (table 2). The 
ICER (£7931) was expressed as the incremental cost per 
QALY gained compared with treatment as usual. NICE 











Screen- and- treat 2 770 909 2771 3805 3.804 –
Treatment- as- usual 1 732 465 1732 3674 3.674 –
Incremental difference 1 038 444 1038 131 0.131 7931 (2622 to 92 459)
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Figure 2 Tornado diagram. CBT, cognitive–behavioural therapy; ICER, incremental cost- effectiveness ratio; PTSD, post- 
traumatic stress disorder; SCID, Structured Clinical Interview for DSM- 5; TSQ, Trauma Screening Questionnaire.
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in England employs guidelines that compare ICER values 
to a willingness- to- pay threshold of £20 000 per QALY. 
Given the ICER is below that threshold, a screen- and- treat 
approach would be considered a cost- effective option 
based on the model inputs.
One-way sensitivity analysis
The sensitivity of the incremental cost- effectiveness ratio 
to an increase or decrease in model input variables is 
shown in the tornado diagram (figure 2). In short, the 
key drivers of the ICER were the overall prevalence of 
PTSD (prev_PTSD), utility of being in the PTSD or no 
PTSD health states (u_PTSD, u_noPTSD), prevalence of 
immediate onset PTSD (prev_IPTSD), the probability of 
recovery with CBT and the costs associated with having 
PTSD (c_PTSD).
Probabilistic sensitivity analysis
The incremental costs and benefits, having run the model 
over 1000 iterations, are presented as a cost- effectiveness 
acceptability curve (figure 3). This curve represents the 
proportion of iterations (out of 1000) that would be 
considered cost- effective at various willingness- to- pay 
thresholds. The screen- and- treat approach was found to 
have an 88% chance of being considered cost- effective 
given a willingness- to- pay threshold of £20 000 per QALY. 
The probabilistic sensitivity analysis was also used to calcu-
late the 95% CI (£2621 to £92 459).
DISCUSSION
The primary aim of the study was to calculate the incre-
mental cost- effectiveness ratio of a screen- and- treat 
approach to identifying and treating PTSD in adults 
following a major incident compared with standard 
care. It offers important system learning for emergency 
response planners as the comparator group represents 
what would likely happen (the counterfactual) if a screen- 
and- treat approach is not implemented. Results show an 
incremental cost- effectiveness ratio of £7931 per QALY 
gained. This is below the willingness- to- pay threshold of 
£20 000 per QALY employed in NICE decision- making 
contexts and would therefore be seen as representing 
value for money. Effectively, although it costs more than 
treatment- as- usual, a screen- and- treat approach delivers 
population health outcomes that are considered to be 
sufficiently better to justify the higher costs. Whether 
this finding warrants utilisation of this approach will ulti-
mately be determined by local decision- makers. Although 
not directly comparable because of the different target 
population, CBT for UK middle- aged adults treated for 
PTSD due to all causes, rather than just for major inci-
dents, was found to be cost- effective, with a net monetary 
benefit per person over 3 years of £32 042.36
The economic model was designed to broadly mirror 
clinical practice, incorporating multiple rounds of 
screening and clinical assessment and changing sensi-

























Willingness to pay threshold (£)
probability S&T cost-effective probability TAU cost-effective
Figure 3 Cost- effectiveness acceptability curve. S&T, screen- and- treat; TAU, treatment- as- usual.
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The model also incorporated heterogeneity in PTSD 
onset (immediate vs delayed) and recovery following 
CBT (full vs partial). The robustness of the results was 
demonstrated by addressing uncertainty through deter-
ministic and probabilistic sensitivity analysis. One limita-
tion, however, was the limited information available on 
the distribution of some model parameters, and in line 
with previous studies we made assumptions on standard 
errors for parameters to create distributions. The strict 
NICE perspective optimises the relevance of the paper 
to UK policy- makers. However, limiting the economic 
analysis to a health and social care perspective may mean 
that our estimate of cost- effectiveness is conservative. For 
example, indirect costs arising from disrupted employ-
ment38 or impaired education39 may be substantial for an 
individual involved in a major incident. Empirical anal-
ysis of the burden of PTSD following the London bomb-
ings found that indirect costs (mostly productivity losses) 
accounted for the majority (64%) of reported costs.34
Another limitation is the absence of data for the impact 
of PTSD on the general population. Utility values for 
adults were based on an Australian study of victims of 
non- terror- related trauma37 and may not be generalisable 
to major incident- exposed adults in the UK. However, 
0.61 is a conservative approximation for PTSD utility in 
adults compared with other economic analyses, which 
potentially reduces the capacity for QALY gains. Another 
Australian study used reported utility values as low as 
0.54 for adults experiencing PTSD.40 These lower utility 
values were used in a UK economic modelling study of 
psychological interventions in a general adult popula-
tion with PTSD.36 In an economic evaluation of treat-
ment for US military personnel, the QALY value used was 
also lower with a mean baseline utility value for PTSD of 
0.56.41 Finally, the model did not factor in the burden of 
comorbidities, relapse, nor the differences in outcomes 
after traumatic events by key demographic factors. For 
example, PTSD comorbid with depression has been esti-
mated to have a utility value of 0.53,37 which is lower than 
the 0.61 assumed in the model. Additional studies are 
needed that evaluate cost- effectiveness of evidence- based 
interventions for high- risk groups.
Our results are potentially generalisable to a variety of 
emergencies, including the current pandemic. Certain 
groups such as those hospitalised for COVID- 19 appear 
to have rates of PTSD that approximate those typical of 
victims of terrorist attacks,42 43 and rates among frontline 
hospital and social care staff have also been reported 
to be high.44 45 Cost- effectiveness calculations will inevi-
tably be impacted by parameter changes arising from 
newly acquired knowledge about rates of disorder in 
different affected groups, and by differences in the 
ease of identifying and engaging various populations. 
Some of these changes, such as the increased availability 
of online screening and treatment, are likely to have 
the effect of reducing costs (and therefore increasing 
cost- effectiveness). Others, such as a high prevalence 
of affected people among immigrants with a limited 
knowledge of the host country language, are likely to 
have the effect of increasing costs. Our model neverthe-
less provides a structure within which to assess the likely 
benefits—in the absence of directly observed data at this 
stage—of instituting screen- and- treat programmes in this 
different context.
With the psychological impact of terrorist attacks in 
recent years still evident across many parts of society, the 
impact of the COVID- 19 pandemic is only just beginning 
to be appreciated. Further analysis might be needed for 
scenarios representing COVID- 19, but in the meantime 
our conclusions provide some helpful implications. With 
both forms of major incident, sequelae involving severe 
psychological conditions including PTSD are inevitable 
features, causing extensive personal and community 
suffering. Addressing these conditions requires active 
investment, planning and delivery at all levels from 
policy- makers, strategic and operational health and care 
teams, and local communities. We hope that the analyses 
in this paper will go some way to drive a more positive atti-
tude among key stakeholders to ensure that services for 
post- traumatic psychological conditions are funded and 
managed effectively.
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